Researcher
Paul Declerck
- Disciplines:Laboratory medicine, Regenerative medicine, Other basic sciences, Other health sciences, Other medical and health sciences, Medical biotechnology, Drug discovery and development, Pharmaceutics
Affiliations
- Therapeutic and Diagnostic Antibodies (Division)
Member
From1 Apr 2013 → 30 Sep 2023
Projects
1 - 10 of 28
- An integrated platform for the identification, isolation and characterization of human clock antibodies.From1 Jul 2021 → TodayFunding: Department Coordination
- VyCAP single cell isolation platform for high-quality single-cell analysisFrom1 Jan 2021 → 31 Dec 2022Funding: BOF - scientific equipment program
- A Pharmacometrics Approach to Improve Dose Individualisation Methods of Biologicals in Patients with Chronic Inflammatory DiseasesFrom13 Oct 2020 → TodayFunding: FWO Strategic Basic Research Grant
- Development and streamlining a validation and implementation workflow for model-informed precision dosing for biologicals and antimicrobialsFrom1 Oct 2020 → 30 Sep 2022Funding: IOF - technology validation in lab
- Advancing DNA-based antibody therapeutics through evaluation and characterization of in vivo expression, complex antibody formats, and delivery formulationsFrom1 Sep 2020 → TodayFunding: FWO fellowships, Foundations, funds and other with scientific goal
- Anti-tau intrabodies for the treatment of Alzheimer’s diseaseFrom1 Feb 2020 → 19 Feb 2024Funding: Baekeland
- Extracellular Vesicle Tracking using surface proteins and Resonance Assays to detect breast Cancer in Early stage (EV-TRACE)From1 Jan 2020 → 31 Dec 2023Funding: FWO Strategic Basic Research (SBO)
- An on-chip single B cell mining platform for rapid development of fully human therapeutic antibodies and for immunoprofiling human antibody responsesFrom1 Oct 2019 → 30 Sep 2022Funding: IOF - technology validation in lab
- Development and validation of sampling and rapid assay methods for vedozilumab and ustekinumab therapeutic drug monitoringFrom1 Dec 2018 → 30 Nov 2020Funding: Foreign private sponsor - undefined
- BIOLOPTIM: implementing therapeutic drug monitoring of biologics for psoriasis and hidradenitis suppurativaFrom1 Oct 2018 → TodayFunding: FWO Applied Biomedical Research (TBM)
Publications
161 - 170 of 197
- Determination of coagulation and fibrinolysis markers upon anti-TAFI treatment in a mouse thromboembolism model(2011)
Authors: E Vercauteren, Jan Emmerechts, M Peeters, Marc Hoylaerts, Paul Declerck, A Gils
Pages: 598 - 599 - Identification and characterisation of monoclonal antibodies that impair the activation of human thrombin activatable fibrinolysis inhibitor through different mechanisms(2011)
Authors: Niraj Mishra, Riet Bammens, Paul Declerck, Ann Gils
Pages: 90 - 101 - Development of an immunological toolbox to detect endogenous and exogenous pectin methylesterase in plant-based food products(2011)
Authors: Evelien Vandevenne, Sandy Van Buggenhout, Paul Declerck, Marc Hendrickx, Ann Van Loey, Ann Gils
Pages: 931 - 939 - Monoclonal antibodies: indications, budget impact and use(2011)
Authors: Steven Simoens, Thomas De Rijdt, Paul Declerck
Pages: 400 - 400 - Identification of a bacterial inhibitor against g-type lysozyme(2011)
Authors: Lise Vanderkelen, Joris Van Herreweghe, Paul Declerck, Chris Michiels, Lien Callewaert
Pages: 1053 - 1064 - High thrombin activatable fibrinolysis inhibitor levels are associated with an increased risk of premature peripheral arterial disease(2011)
Authors: Ann Gils, Paul Declerck
Pages: 254 - 258 - Evaluation of the profibrinolytic properties of an anti-TAFI monoclonal antibody in a mouse thromboembolism model(2011)
Authors: Jan Emmerechts, Marc Hoylaerts, Paul Declerck, Ann Gils
Pages: 4615 - 4622 - Advances in understanding pectin methylesterase inhibitor in kiwi fruit: an immunological approach(2011)
Authors: Evelien Vandevenne, Stefanie Christiaens, Sandy Van Buggenhout, Ruben Jolie, Thomas Duvetter, Paul Declerck, Marc Hendrickx, Ann Gils, Ann Van Loey
Pages: 287 - 298 - Use of mouse models to study plasminogen activator inhibitor-1(2011)
Authors: Paul Declerck, Ann Gils
Pages: 77 - 104 - Complex formation of urokinase-type plasminogen activator with plasminogen activator inhibitor-1 enhances its potential to promote extravasation of monocytes(2011)
Authors: B Uhl, M Praetner, M Lerchenberger, Paul Declerck, S Kanse, F Krombach, CA Reichel
Pages: 335 - 335
Patents
1 - 1 of 1
- Dual targeting of tafi and pai-1 (Inventor)
Linked dataset
1 - 1 of 1